101 GLEN LENNOX DRIVE, CHAPEL HILL, NC
Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026
Tenax Therapeutics Enters Supply Agreement with Orion Corporation
Executive Employment Agreement Amendments for Tenax Therapeutics
Stockholder Meeting Results - Directors Elected at Tenax Therapeutics
Reports First Quarter 2026 Financial Results and Provides Corporate Update
Annual Report to Security Holders
Appoints Thomas R. Staab, II as Chief Financial Officer
Financial Results, Press Release
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report